Riskpilot← Back to searchSign inGet full accessBIOFYN ApS
APSIn liquidationCVR 29142378Willemoesvej 5Forskning og eksperimentel udvikling indenfor bioteknologi · NACE 721100Est. 2005— employees
Revenue 2017
DKK -10K
+11% vs 2016
EBITDA margin
100.0%
-11% vs 2016
Equity ratio
-51.6%
Financial strength
Net profit 2017
DKK 42
+101% vs 2016
| Revenue | DKK -10K | +11% |
| EBITDA | DKK -10K | -11% |
| Net profit | DKK 42 | +101% |
| Total assets | DKK 104K | +1391% |
| Equity | DKK -54K | +0% |
| Employees | — | — |
Legal name
BIOFYN ApS
CVR number
29142378
Legal form
Anpartsselskab
NACE code
721100 · Forskning og eksperimentel udvikling indenfor bioteknologi
Founded
14. oktober 2005
Share capital
DKK 125.000
Employees
—
VAT registered
No
Audit selected
No
Last report
2017-06-30
Financial year
January – December
Signatory rights
Virksomheden tegnes af en likvidator
Address
Willemoesvej 5
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 |
|---|---|---|---|---|---|---|
| Revenue | -8 | -37 | -8 | -8 | -9 | -10 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -5 | -13 | -8 | -8 | -9 | -10 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -5 | -13 | -8 | -8 | -9 | -10 |
| Net financials | 0 | -1 | -1 | -1 | -1 | -3 |
| Profit before tax | -5 | -14 | -10 | -10 | -11 | -13 |
| Tax | 2 | 12 | -8 | -4 | -2 | -13 |
| Net profit | -6 | -26 | -2 | -6 | -8 | 0 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 |
|---|---|---|---|---|---|---|
| Total assets | 5 | 19 | 18 | 14 | 7 | 104 |
| Equity | -12 | -38 | -40 | -45 | -54 | -54 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 17 | 57 | 58 | 59 | 61 | 158 |
| Total debt | 17 | 57 | 58 | 59 | 61 | 158 |
EBITDA margin
-1021500.0%
This company
15.8%
Market median
-6465290% vs market
20122017
Equity ratio
-51.6%
This company
38.2%
Market median
-235% vs market
20122017
Return on equity
4200.0%
This company
18.4%
Market median
+22726% vs market
20122017
Net profit margin
4200.0%
This company
8.1%
Market median
+51752% vs market
20122017
Asset turnover
-0.10×
This company
1.12×
Market median
-109% vs market
20122017
Debt / equity
2.94×
This company
0.62×
Market median
-374% vs market
20122017
- Annual report 2017Filed via CVR / Virk · Period 2016-07-01 – 2017-06-30
- Annual report 2016Filed via CVR / Virk · Period 2015-07-01 – 2016-06-30
- Annual report 2015Filed via CVR / Virk · Period 2014-07-01 – 2015-06-30
- Annual report 2014Filed via CVR / Virk · Period 2013-07-01 – 2014-06-30
- Annual report 2013Filed via CVR / Virk · Period 2012-07-01 – 2013-06-30
- Annual report 2012Filed via CVR / Virk · Period 2011-07-01 – 2012-06-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
HL Unofficial title | Unofficial title | 2017 | — | — |
JE Management | Management | 2005 | — | — |
KP Management | Management | 2006 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2009 | — | — | |
| Chairman | 2005 | — | — | |
| Board of Directors | 2005 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Polyteknisk Forskning og Udvikling ApS | Company | 100.0% | 100.0% | 2015 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of BIOFYN ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Hans Lindstrøm Svendsen | Unofficial title | 0 companies |
| John Emil Engell | Management | 0 companies |
| Kristian Pontoppidan Lyngborg | Management | 0 companies |
| Dorthe Karlshøj Poulsen | Board of Directors | 0 companies |
| Jens Sønderberg Frederiksen | Chairman | 0 companies |
| Trine Albers Huusfeldt | Board of Directors | 0 companies |